Cassady Schiller Wealth Management LLC Buys 87 Shares of Johnson & Johnson (NYSE:JNJ)

Cassady Schiller Wealth Management LLC boosted its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.9% in the second quarter, Holdings Channel reports. The firm owned 9,437 shares of the company’s stock after purchasing an additional 87 shares during the quarter. Johnson & Johnson comprises about 0.9% of Cassady Schiller Wealth Management LLC’s holdings, making the stock its 24th biggest position. Cassady Schiller Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,675,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the business. Palisade Capital Management LLC NJ increased its holdings in Johnson & Johnson by 0.3% in the 1st quarter. Palisade Capital Management LLC NJ now owns 93,141 shares of the company’s stock valued at $16,507,000 after buying an additional 250 shares during the period. Lmcg Investments LLC bought a new position in Johnson & Johnson in the 1st quarter valued at about $12,462,000. Capital Wealth Planning LLC increased its holdings in Johnson & Johnson by 14.0% in the 1st quarter. Capital Wealth Planning LLC now owns 916,575 shares of the company’s stock valued at $162,445,000 after buying an additional 112,890 shares during the period. Tandem Investment Advisors Inc. increased its holdings in Johnson & Johnson by 4.8% in the 1st quarter. Tandem Investment Advisors Inc. now owns 326,505 shares of the company’s stock valued at $57,867,000 after buying an additional 15,003 shares during the period. Finally, Tcwp LLC bought a new position in Johnson & Johnson in the 1st quarter valued at about $946,000. Institutional investors own 68.59% of the company’s stock.

Johnson & Johnson Trading Up 0.1 %

JNJ opened at $177.01 on Thursday. The firm has a market capitalization of $462.79 billion, a price-to-earnings ratio of 24.65, a PEG ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The company’s 50 day moving average price is $168.35 and its two-hundred day moving average price is $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The firm had revenue of $23.79 billion for the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.60 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson declared that its board has authorized a stock buyback program on Wednesday, September 14th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 1.2% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s management believes its stock is undervalued.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.95%.

Insider Transactions at Johnson & Johnson

In related news, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider William Hait sold 15,000 shares of the business’s stock in a transaction on Monday, October 24th. The shares were sold at an average price of $171.55, for a total transaction of $2,573,250.00. Following the transaction, the insider now owns 80,236 shares in the company, valued at approximately $13,764,485.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Peter Fasolo sold 22,864 shares of the business’s stock in a transaction on Wednesday, October 19th. The shares were sold at an average price of $164.50, for a total transaction of $3,761,128.00. Following the transaction, the vice president now owns 114,676 shares in the company, valued at approximately $18,864,202. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 212,646 shares of company stock worth $36,791,022. Company insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on JNJ. Atlantic Securities decreased their target price on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Wednesday, October 19th. Citigroup decreased their price target on shares of Johnson & Johnson from $201.00 to $198.00 in a report on Wednesday, October 5th. Raymond James decreased their price target on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating on the stock in a report on Wednesday, October 19th. Bank of America decreased their price target on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Finally, Credit Suisse Group began coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $181.33.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.